Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Magnetic Resonance Spectroscopy 270 Specimen Handling 259 pembrolizumab 235 Cyclophosphamide 220 Radiotherapy 208 Nivolumab 171 Cisplatin 162 Carboplatin 150 Biopsy 148 Radiosurgery 130 fludarabine 125 Blood Specimen Collection 117 Gemcitabine 113 Paclitaxel 111 Surveys and Questionnaires 109 Standard of Care 106 venetoclax 97 Dexamethasone 96 Bevacizumab 95 Radiation 88 Rituximab 84 Capecitabine 82 Cytarabine 79 Oxaliplatin 77 Doxorubicin 76 Drug Therapy 75 durvalumab 73 Ipilimumab 72 fludarabine phosphate 69 atezolizumab 69

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × DLL3 protein, human × 90 days × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡